Identification

Name
Beraprost
Accession Number
DB05229
Type
Small Molecule
Groups
Investigational
Description

Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
35E3NJJ4O6
CAS number
88430-50-6
Weight
Average: 420.4738
Monoisotopic: 420.191268713
Chemical Formula
C24H29NaO5
InChI Key
YTCZZXIRLARSET-VJRSQJMHSA-M
InChI
InChI=1S/C24H30O5.Na/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28;/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28);/q;+1/p-1/b13-12+;/t15?,17-,19+,20+,21-,23-;/m0./s1
IUPAC Name
sodium 4-[(2S,3R,4R,6S)-4-hydroxy-3-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-7-oxatricyclo[6.4.0.0²,⁶]dodeca-1(12),8,10-trien-9-yl]butanoate
SMILES
[Na+].[H][[email protected]]12C[[email protected]@H](O)[[email protected]](\C=C\[[email protected]@H](O)C(C)CC#CC)[[email protected]@]1([H])C1=CC=CC(CCCC([O-])=O)=C1O2

Pharmacology

Indication

For the treatment of pulmonary hypertension.

Structured Indications
Not Available
Pharmacodynamics

Beraprost is a stable, orally active prostacyclin analogue with vasodilatory, antiplatelet and cytoprotective effects. Beraprost is generally well tolerated and appears to be an effective agent in the treatment of patients with Buerger's disease and arteriosclerosis obliterans. Comparative data from a large randomised trial indicated that the drug appears as effective as ticlopidine in patients with these conditions. In patients with intermittent claudication, significant benefits of beraprost compared with placebo were reported in a randomised clinical trial; however, the use of beraprost in these patients is not supported by recent preliminary unpublished data from a large, phase III, placebo-controlled study. Limited data suggest some efficacy with long-term beraprost treatment of patients with PAH, where options are few and where oral administration of the drug could be a considerable advantage over intravenous prostacyclin (PGI2) therapy.

Mechanism of action

Beraprost acts by binding to prostacyclin membrane receptors ultimately inhibiting the release of Ca2+ from intracellular storage sites. This reduction in the influx of Ca2+ has been postulated to cause relaxation of the smooth muscle cells and vasodilation.

TargetActionsOrganism
UProstacyclin receptorNot AvailableHuman
Absorption

Oral bioavailability is 50–70%.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

35–40 minutes

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabBeraprost may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Beraprost can be increased when it is combined with Abiraterone.Approved
AceclofenacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolBeraprost may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Beraprost is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Adapalene.Approved
AlclofenacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlminoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Beraprost is combined with Aloxiprin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Beraprost.Approved, Investigational
AlteplaseBeraprost may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Beraprost may increase the anticoagulant activities of ALX-0081.Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Beraprost is combined with Aminosalicylic Acid.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Beraprost.Approved
AncrodBeraprost may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Andrographolide.Investigational
AnisodamineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Anisodamine.Investigational
AnistreplaseBeraprost may increase the anticoagulant activities of Anistreplase.Approved
AntipyrineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Antipyrine.Approved
Antithrombin III humanBeraprost may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Beraprost is combined with Apixaban.Approved
ApocyninThe therapeutic efficacy of Beraprost can be decreased when used in combination with Apocynin.Investigational
ApremilastThe therapeutic efficacy of Beraprost can be decreased when used in combination with Apremilast.Approved, Investigational
AprotininThe therapeutic efficacy of Beraprost can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinBeraprost may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanBeraprost may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinBeraprost may increase the anticoagulant activities of Astaxanthin.Investigational
AzapropazoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Azelastine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Beraprost is combined with Balsalazide.Approved, Investigational
BatroxobinBeraprost may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminBeraprost may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinBeraprost may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BendazacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bendazac.Experimental
BenorilateThe therapeutic efficacy of Beraprost can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Benzydamine.Approved
BevoniumThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bevonium.Experimental
BivalirudinBeraprost may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseBeraprost may increase the anticoagulant activities of Brinase.Experimental
BromfenacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bucillamine.Investigational
BufexamacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bufexamac.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Beraprost.Experimental
BumadizoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bumadizone.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Beraprost.Investigational
CangrelorBeraprost may increase the anticoagulant activities of Cangrelor.Approved
CarbamazepineThe metabolism of Beraprost can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe metabolism of Beraprost can be decreased when combined with Celecoxib.Approved, Investigational
CertoparinBeraprost may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Chloroquine.Approved, Vet Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Beraprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CilostazolCilostazol may increase the anticoagulant activities of Beraprost.Approved
Citric AcidBeraprost may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClonixinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Clonixin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Beraprost.Approved, Nutraceutical
CloricromenBeraprost may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneBeraprost may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Beraprost can be decreased when combined with Clotrimazole.Approved, Vet Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Beraprost is combined with Collagenase clostridium histolyticum.Approved, Investigational
CrisaboroleThe metabolism of Beraprost can be decreased when combined with Crisaborole.Approved
CurcuminThe therapeutic efficacy of Beraprost can be decreased when used in combination with Curcumin.Investigational
D-LimoneneThe therapeutic efficacy of Beraprost can be decreased when used in combination with D-Limonene.Investigational
Dabigatran etexilateBeraprost may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Beraprost can be decreased when it is combined with Dabrafenib.Approved
DalteparinBeraprost may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidBeraprost may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanBeraprost may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Beraprost.Approved, Investigational
DeferasiroxThe serum concentration of Beraprost can be increased when it is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Beraprost.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Beraprost is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Beraprost is combined with dersalazine.Investigational
DesirudinBeraprost may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseBeraprost may increase the anticoagulant activities of Desmoteplase.Investigational
DextranBeraprost may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Beraprost may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Beraprost may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Beraprost may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DicoumarolBeraprost may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Beraprost is combined with Diflunisal.Approved
DiphenadioneBeraprost may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Beraprost.Approved
DitazoleBeraprost may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaBeraprost may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Droxicam.Approved
DuvelisibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Beraprost can be decreased when used in combination with E-6201.Investigational
Edetic AcidBeraprost may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBeraprost may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Beraprost can be decreased when combined with Efavirenz.Approved, Investigational
EnoxaparinBeraprost may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Beraprost.Approved, Investigational
EpirizoleThe therapeutic efficacy of Beraprost can be decreased when used in combination with Epirizole.Approved
EplivanserinBeraprost may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineBeraprost may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolEpoprostenol may increase the antiplatelet activities of Beraprost.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Beraprost.Approved, Investigational
EtanerceptThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ethenzamide.Experimental
Ethyl biscoumacetateBeraprost may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Beraprost can be decreased when used in combination with Evening primrose oil.Approved, Investigational
exisulindThe therapeutic efficacy of Beraprost can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Felbinac.Experimental
FelodipineThe metabolism of Beraprost can be decreased when combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ferulic acid.Experimental
FibrinolysinBeraprost may increase the anticoagulant activities of Fibrinolysin.Investigational
FloctafenineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluindioneBeraprost may increase the anticoagulant activities of Fluindione.Investigational
FlunixinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Flunoxaprofen.Experimental
FlurbiprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FondaparinuxBeraprost may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumBeraprost may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosphenytoinThe metabolism of Beraprost can be increased when combined with Fosphenytoin.Approved
GabexateBeraprost may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Beraprost.Approved
GuacetisalThe risk or severity of adverse effects can be increased when Beraprost is combined with Guacetisal.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Beraprost is combined with Hemoglobin crosfumaril.Experimental
HeparinBeraprost may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Higenamine.Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Beraprost.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Beraprost is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Beraprost.Approved
IbudilastIbudilast may increase the anticoagulant activities of Beraprost.Approved, Investigational
IbuprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Beraprost can be decreased when used in combination with Icatibant.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Beraprost.Approved, Nutraceutical
IdraparinuxBeraprost may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Beraprost.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Beraprost.Investigational
IloprostIloprost may increase the antiplatelet activities of Beraprost.Approved, Investigational
Imidazole salicylateThe therapeutic efficacy of Beraprost can be decreased when used in combination with Imidazole salicylate.Experimental
IndobufenBeraprost may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Indoprofen.Withdrawn
IrbesartanThe metabolism of Beraprost can be decreased when combined with Irbesartan.Approved, Investigational
IsoxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Isoxicam.Withdrawn
KebuzoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Beraprost.Investigational
KetoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ketorolac.Approved
LapatinibThe metabolism of Beraprost can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Leflunomide.Approved, Investigational
LepirudinBeraprost may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanBeraprost may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Beraprost.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Beraprost.Experimental
LisofyllineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lisofylline.Investigational
LonazolacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Beraprost can be decreased when combined with Losartan.Approved
LoxoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumacaftorThe serum concentration of Beraprost can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Beraprost can be decreased when used in combination with Magnesium salicylate.Approved
MasoprocolThe therapeutic efficacy of Beraprost can be decreased when used in combination with Masoprocol.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mefenamic acid.Approved
MelagatranBeraprost may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Beraprost is combined with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Beraprost can be decreased when used in combination with Metamizole.Investigational, Withdrawn
Methyl salicylateThe risk or severity of adverse effects can be increased when Beraprost is combined with Methyl salicylate.Approved, Vet Approved
MifepristoneThe serum concentration of Beraprost can be increased when it is combined with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Beraprost.Approved
MizoribineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mizoribine.Investigational
MofebutazoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mofebutazone.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nabumetone.Approved
NadroparinBeraprost may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Naftifine.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Beraprost.Investigational
NaproxenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Naproxen.Approved, Vet Approved
NepafenacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nepafenac.Approved
NifenazoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Niflumic Acid.Approved
NilotinibThe metabolism of Beraprost can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Beraprost is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Beraprost is combined with Obinutuzumab.Approved
OlopatadineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Beraprost is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Beraprost.Approved, Nutraceutical
OrgoteinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Orgotein.Vet Approved
OtamixabanBeraprost may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Oxaprozin.Approved
OxyphenbutazoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OzagrelBeraprost may increase the anticoagulant activities of Ozagrel.Investigational
ParecoxibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Parecoxib.Approved
ParnaparinBeraprost may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParthenolideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Parthenolide.Investigational
Pentaerythritol TetranitrateBeraprost may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Beraprost.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Beraprost.Approved, Investigational
PhenindioneBeraprost may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Beraprost can be increased when combined with Phenobarbital.Approved
PhenprocoumonBeraprost may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Beraprost can be increased when combined with Phenytoin.Approved, Vet Approved
PicotamideBeraprost may increase the anticoagulant activities of Picotamide.Experimental
PimecrolimusThe therapeutic efficacy of Beraprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PioglitazoneThe metabolism of Beraprost can be decreased when combined with Pioglitazone.Approved, Investigational
PirfenidoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiroxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Pirprofen.Experimental
PranoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Beraprost.Approved
PrimidoneThe metabolism of Beraprost can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Beraprost can be decreased when used in combination with Propacetamol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Proquazone.Experimental
Protein CBeraprost may increase the anticoagulant activities of Protein C.Approved
Protein S humanBeraprost may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBeraprost may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299The therapeutic efficacy of Beraprost can be decreased when used in combination with PTC299.Investigational
QuinineThe metabolism of Beraprost can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Beraprost can be decreased when combined with Rabeprazole.Approved, Investigational
RamatrobanRamatroban may increase the anticoagulant activities of Beraprost.Investigational
ResveratrolThe therapeutic efficacy of Beraprost can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
ReteplaseBeraprost may increase the anticoagulant activities of Reteplase.Approved
ReviparinBeraprost may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Beraprost.Approved
RifampicinThe metabolism of Beraprost can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Beraprost can be increased when combined with Rifapentine.Approved
RivaroxabanBeraprost may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RosiglitazoneThe metabolism of Beraprost can be decreased when combined with Rosiglitazone.Approved, Investigational
SalicylamideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Beraprost is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Beraprost can be decreased when used in combination with Salsalate.Approved
SarpogrelateBeraprost may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseBeraprost may increase the anticoagulant activities of Saruplase.Experimental
SecobarbitalThe metabolism of Beraprost can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagBeraprost may increase the anticoagulant activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Beraprost can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Beraprost can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Beraprost can be decreased when used in combination with Serrapeptase.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Beraprost.Approved, Vet Approved
SRT501The therapeutic efficacy of Beraprost can be decreased when used in combination with SRT501.Investigational
StreptokinaseBeraprost may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulfamethoxazoleThe metabolism of Beraprost can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Beraprost can be decreased when used in combination with Sulindac.Approved
SulodexideBeraprost may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Beraprost can be decreased when used in combination with Suxibuzone.Experimental
TamoxifenThe metabolism of Beraprost can be decreased when combined with Tamoxifen.Approved
TarenflurbilThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tarenflurbil.Investigational
TenecteplaseBeraprost may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe metabolism of Beraprost can be decreased when combined with Teriflunomide.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Beraprost.Investigational
Tiaprofenic acidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tiaprofenic acid.Approved
TicagrelorBeraprost may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Beraprost.Approved
TinoridineThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tinoridine.Investigational
TinzaparinBeraprost may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolBeraprost may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Beraprost.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Beraprost.Approved
Tolfenamic AcidThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tolmetin.Approved
TopiroxostatThe metabolism of Beraprost can be decreased when combined with Topiroxostat.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Beraprost is combined with Tositumomab.Approved, Investigational
TranilastThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tranilast.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Beraprost.Approved
TreprostinilTreprostinil may increase the antiplatelet activities of Beraprost.Approved, Investigational
TribenosideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tribenoside.Experimental
TriflusalBeraprost may increase the anticoagulant activities of Triflusal.Approved, Investigational
TrimethoprimThe metabolism of Beraprost can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe therapeutic efficacy of Beraprost can be decreased when used in combination with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Beraprost is combined with Trolamine salicylate.Approved
TroxerutinBeraprost may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseBeraprost may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe therapeutic efficacy of Beraprost can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Beraprost.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Beraprost.Approved
WarfarinBeraprost may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBeraprost may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe therapeutic efficacy of Beraprost can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Beraprost can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe therapeutic efficacy of Beraprost can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
  1. Lin H, Lee JL, Hou HH, Chung CP, Hsu SP, Juan SH: Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells. J Cell Physiol. 2008 Feb;214(2):434-41. [PubMed:17620284]
  2. Melian EB, Goa KL: Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs. 2002;62(1):107-33. [PubMed:11790158]
External Links
PubChem Compound
23663404
PubChem Substance
175426958
ChemSpider
5293168
ChEMBL
CHEMBL435883
Wikipedia
Beraprost
ATC Codes
B01AC19 — Beraprost
MSDS
Download (15.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Adult Males / Pharmacokinetics of TRK-100-STP1
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentRenal Insufficiency,Chronic1
4TerminatedPreventionType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00811 mg/mLALOGPS
logP3.81ALOGPS
logP3.6ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)4.2ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area89.82 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity123.56 m3·mol-1ChemAxon
Polarizability44.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8736
Blood Brain Barrier+0.7754
Caco-2 permeable+0.5868
P-glycoprotein substrateSubstrate0.6165
P-glycoprotein inhibitor INon-inhibitor0.9641
P-glycoprotein inhibitor IINon-inhibitor0.9395
Renal organic cation transporterNon-inhibitor0.9342
CYP450 2C9 substrateNon-substrate0.7409
CYP450 2D6 substrateNon-substrate0.8255
CYP450 3A4 substrateNon-substrate0.5132
CYP450 1A2 substrateInhibitor0.5177
CYP450 2C9 inhibitorNon-inhibitor0.8578
CYP450 2D6 inhibitorNon-inhibitor0.8834
CYP450 2C19 inhibitorNon-inhibitor0.7827
CYP450 3A4 inhibitorInhibitor0.6633
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7365
Ames testAMES toxic0.5331
CarcinogenicityNon-carcinogens0.9445
BiodegradationNot ready biodegradable0.5301
Rat acute toxicity3.6575 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8871
hERG inhibition (predictor II)Non-inhibitor0.9611
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as coumarans. These are compounds containing the coumaran skeleton, which consists of a benzene ring fused to a 2,3-dihydrofuran ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Coumarans
Sub Class
Not Available
Direct Parent
Coumarans
Alternative Parents
Alkyl aryl ethers / Benzenoids / Secondary alcohols / Cyclic alcohols and derivatives / Carboxylic acid salts / Oxacyclic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Organic zwitterions / Organic sodium salts
show 3 more
Substituents
Coumaran / Alkyl aryl ether / Benzenoid / Cyclic alcohol / Carboxylic acid salt / Secondary alcohol / Monocarboxylic acid or derivatives / Ether / Carboxylic acid / Carboxylic acid derivative
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Gene Name
PTGIR
Uniprot ID
P43119
Uniprot Name
Prostacyclin receptor
Molecular Weight
40955.485 Da
References
  1. Melian EB, Goa KL: Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs. 2002;62(1):107-33. [PubMed:11790158]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Fukazawa T, Yajima K, Miyamoto Y: Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro. Yakugaku Zasshi. 2008 Oct;128(10):1459-65. [PubMed:18827466]

Drug created on October 21, 2007 16:24 / Updated on December 01, 2017 15:35